NCT02974621: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 9 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02974621 |
|---|---|
| Title | A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 7, 2017 |
| Completion date | Dec. 31, 2022 |
| Required reporting date | Dec. 31, 2023, midnight |
| Actual reporting date | Jan. 9, 2024 |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 9 |